Consensus Guidelines Metastatic NSCLC: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy
Published in 2011 - Ann Oncol (2011) 22 (7): 1507-1519.
Authors: E. Felip, C. Gridelli, P. Baas, R. Rosell, R. Stahel
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Published in 2011 - Ann Oncol (2011) 22 (7): 1507-1519.
Authors: E. Felip, C. Gridelli, P. Baas, R. Rosell, R. Stahel
Leading cancer institutes and organisations are combining forces to streamline cross border cancer research in Europe.
From 22 March 2011, EU citizens have access to information on thousands of authorised pharmaceutical clinical trials that are underway in the EU.
At a time when the effects of paediatric oncology research have meant that more and more children survive cancer, its funding is too low and dependent on short-term grant.
February 28th, 2011 is Rare Disease Day. All over the world, rare disease patient organisations and their partners will join forces to create awareness of rare diseases and the millions of people affected by them.
Spain
Young patients joined MEPs, experts in paediatric oncology and others to discuss how the rapid rate of progress previously established in childhood cancer is being forcibly arrested by the implementation of recent EU legislation.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.